Search results
Showing 16 to 24 of 24 results for osimertinib
Discontinued Reference number: GID-TA11289
Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA621)
This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 654
Evidence-based recommendations on durvalumab (Imfinzi) with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer in adults.
Show all sections
In development Reference number: GID-TA11589 Expected publication date: TBC
This guidance has been updated and replaced by NICE technology appraisal guidance 653.
This guidance has been updated and replaced by NICE technology appraisal guidance 1043.
Past technology appraisal appeals and decisions
This document describes a real-world evidence framework that aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence
We have also recommended osimertinib for routine use on the NHS today.